AlphAIalphai — Financial news for AI agents
globenewswire.comAUG 192 min read$CAPR

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Capricor Therapeutics (CAPR) faces a class action lawsuit over alleged securities violations. The suit claims the company and executives failed to disclose material information between December 17, 2025, and July 26, 2026. The FDA criticized changes to the statistical analysis plan for Capricor's lead product, Deramiocel, causing the stock to drop 64% on July 27, 2026. Investors have until September 28, 2026, to join the lawsuit.

Original reporting
globenewswire.com
Published Aug 19, 2026, 2:32 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 6:52 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefRegulation
Primary signal
$CAPR
Bearish
high confidence
Mentioned
$CAPR
Relevance
7/10
alphai data visualization · based on globenewswire.com
Decision brief

The 30-second read

$CAPRBearishMed
01

Why it matters

The class action alleges nondisclosure of material changes to the statistical analysis plan for its BLA, leading to a sharp price decline.

02

Market read

The lawsuit introduces significant legal risk for CAPR shareholders, driving immediate negative price pressure.

03

What to watch

Potential for settlement negotiations that could mitigate downside before a formal court ruling.

Relevance 7/10Novelty 8/10Timing: pre-market July 27, 2026

Background

Capricor Therapeutics (NASDAQ: CAPR) is a clinical-stage biotech developing the gene therapy Deramiocel.

Company-level read

Ticker impact

$CAPRBearishHigh confidence
Context

Capricor Therapeutics disclosed a class action securities lawsuit alleging failure to disclose material information, causing the stock to drop 64% to $7.00.

Expected impact

Further downside pressure likely until lawsuit resolution or settlement.

Evidence & confidence

The lawsuit is a fresh, material legal event for a listed biotech; the stock already fell sharply on the news, indicating strong market reaction.

Market effects

Sector

Biotech sector may see heightened scrutiny on trial data disclosures.

Regional

US biotech investors may reduce exposure to small-cap clinical-stage firms.

Global

Limited to investors with exposure to CAPR; no broad macro effect.

Counterpoint

What could challenge this read

If the lawsuit is dismissed or settled favorably, the stock could rebound sharply.

Key entities

  • Company
    Capricor Therapeutics, Inc.

    Subject of the class action lawsuit.

  • Law Firm
    Kahn Swick & Foti, LLC

    Notifier of the class action to investors.

Read at source← All news

Related articles

AUG 21
$CAPRMed

/C O R R E C T I O N -- Kessler Topaz Meltzer & Check, LLP/

Capricor Therapeutics (CAPR) faces a securities fraud class action lawsuit for alleged misstatements about its lead product candidate's statistical analysis plan and FDA compliance. The lawsuit covers investments between December 17, 2025, and July 26, 2026, with a deadline to seek lead plaintiff status on September 28, 2026. The FDA's briefing documents revealed unapproved changes to the analysis plan, causing CAPR's stock to drop 64% on July 27, 2026.

prnewswire.com2 min
AUG 21
$CAPRLow

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

A class action lawsuit was filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges securities fraud, claiming the company misrepresented its lead product candidate's statistical analysis plan and FDA compliance. The FDA's briefing documents revealed disagreements with Capricor's changes, causing the stock to drop 64%. Investors have until September 28, 2026, to seek lead plaintiff status.

prnewswire.com2 min
AUG 20
$CAPRLowAI 8/10

Capricor Therapeutics, Inc. Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges misstatements about the company's lead product candidate and FDA compliance. The stock dropped 64% on July 27, 2026, following FDA briefing documents. Investors have until September 28, 2026, to seek lead plaintiff status.

globenewswire.com2 min
AUG 20
$CAPRLow

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact SueWallSt

Capricor Therapeutics (CAPR) faces a securities class action lawsuit after shares dropped 78.7% following FDA briefing documents and an advisory committee vote against its drug. Investors allege undisclosed changes to the statistical analysis plan. The class period is December 17, 2025, to July 26, 2026, with a lead plaintiff deadline of September 28, 2026.

prnewswire.com2 min
AUG 20
$CAPRMedAI 8/10

Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?

Capricor Therapeutics (CAPR) shares rose 58% to $6.65 after the FDA agreed to review 24-month data for its Duchenne muscular dystrophy treatment, deramiocel. The company plans to submit the data, potentially delaying the FDA's decision. CAPR remains 66% below its July 24 close after a regulatory setback. The FDA and advisory panel had raised concerns about the treatment's effectiveness and data analysis. CAPR had $237.9 million in cash as of June 30.

yahoo.com2 min
AUG 18
$CAPRMedAI 8/10

CAPR Stock News: Capricor Therapeutics Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 64% Stock Drop

Capricor Therapeutics (NASDAQ:CAPR) was sued for alleged securities fraud tied to its Deramiocel BLA. The complaint cites alleged misstatements about the therapy and the integrity of clinical data, including changes to a pre-specified statistical analysis plan before FDA resubmission. The stock fell about 64.5% on July 27, 2026 after FDA briefing documents.

prnewswire.com4 min